open access

Vol 7, No 6 (2011)
Review paper
Published online: 2012-02-27
Get Citation

Pemetrexed in the treatment of non-small-cell lung cancer and malignant pleural mesothelioma

Dariusz M. Kowalski, Paweł Krawczyk, Piotr Jaśkiewicz, Paweł Badurak, Maciej Krzakowski
Onkol. Prak. Klin 2011;7(6):292-300.

open access

Vol 7, No 6 (2011)
REVIEW ARTICLES
Published online: 2012-02-27

Abstract

Lung cancer — non-small-cell (NSCLC) in 85% of patients — is currently leading cause of cancer-related mortality in Poland and worldwide. Malignant pleural mesothelioma is a rare malignancy, but prognosis
is poor. In about 60% of patients with NSCLC the disease is inoperable (locally advanced or metastatic).
Pleural mesothelioma is diagnosed in advanced stage in majority of patients. Palliative treatment of patients with NSCLC and malignant pleural mesothelioma is based on chemotherapy. Platinum-based
doublets with third generation drugs are standard in the first line treatment of advanced (metastatic) NSCLC. Pemetrexed and cisplatin-containing chemotherapy is most essential palliative management in
advanced malignant pleural mesothelioma. Among the range of recommended third-generation drugs pemetrexed is also used in the treatment NSCLC. Histology is the predictive factor for pemetrexed efficacy
in NSCLC. Pemetrexed is also used in the second-line treatment of NSCLC cancer after failure of platinum-based initial chemotherapy. The new indication for pemetrexed is maintenance treatment after
first-line chemotherapy in patients with at least disease stabilization.

Abstract

Lung cancer — non-small-cell (NSCLC) in 85% of patients — is currently leading cause of cancer-related mortality in Poland and worldwide. Malignant pleural mesothelioma is a rare malignancy, but prognosis
is poor. In about 60% of patients with NSCLC the disease is inoperable (locally advanced or metastatic).
Pleural mesothelioma is diagnosed in advanced stage in majority of patients. Palliative treatment of patients with NSCLC and malignant pleural mesothelioma is based on chemotherapy. Platinum-based
doublets with third generation drugs are standard in the first line treatment of advanced (metastatic) NSCLC. Pemetrexed and cisplatin-containing chemotherapy is most essential palliative management in
advanced malignant pleural mesothelioma. Among the range of recommended third-generation drugs pemetrexed is also used in the treatment NSCLC. Histology is the predictive factor for pemetrexed efficacy
in NSCLC. Pemetrexed is also used in the second-line treatment of NSCLC cancer after failure of platinum-based initial chemotherapy. The new indication for pemetrexed is maintenance treatment after
first-line chemotherapy in patients with at least disease stabilization.
Get Citation

Keywords

pemetrexed, chemotherapy, non-small-cell lung cancer, malignant pleural mesothelioma

About this article
Title

Pemetrexed in the treatment of non-small-cell lung cancer and malignant pleural mesothelioma

Journal

Oncology in Clinical Practice

Issue

Vol 7, No 6 (2011)

Article type

Review paper

Pages

292-300

Published online

2012-02-27

Bibliographic record

Onkol. Prak. Klin 2011;7(6):292-300.

Keywords

pemetrexed
chemotherapy
non-small-cell lung cancer
malignant pleural mesothelioma

Authors

Dariusz M. Kowalski
Paweł Krawczyk
Piotr Jaśkiewicz
Paweł Badurak
Maciej Krzakowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl